PL3188725T3 - Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawania - Google Patents
Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawaniaInfo
- Publication number
- PL3188725T3 PL3188725T3 PL15838800T PL15838800T PL3188725T3 PL 3188725 T3 PL3188725 T3 PL 3188725T3 PL 15838800 T PL15838800 T PL 15838800T PL 15838800 T PL15838800 T PL 15838800T PL 3188725 T3 PL3188725 T3 PL 3188725T3
- Authority
- PL
- Poland
- Prior art keywords
- inhibitor
- levodopa
- administration
- pharmaceutical compositions
- dopamine decarboxylase
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229940123736 Decarboxylase inhibitor Drugs 0.000 title 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 239000003954 decarboxylase inhibitor Substances 0.000 title 1
- 229960003638 dopamine Drugs 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451034A SE538425C2 (en) | 2014-09-04 | 2014-09-04 | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| SE1550344 | 2015-03-24 | ||
| EP15838800.9A EP3188725B1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| PCT/SE2015/050939 WO2016036308A1 (en) | 2014-09-04 | 2015-09-04 | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3188725T3 true PL3188725T3 (pl) | 2021-08-02 |
Family
ID=55440194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL15838800T PL3188725T3 (pl) | 2014-09-04 | 2015-09-04 | Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawania |
| PL20200070.9T PL3782617T3 (pl) | 2014-09-04 | 2015-09-04 | Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20200070.9T PL3782617T3 (pl) | 2014-09-04 | 2015-09-04 | Farmaceutyczne kompozycje żelowe zawierające lewodopę, karbidopę i entakapon |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10071069B2 (enExample) |
| EP (3) | EP3782617B1 (enExample) |
| JP (2) | JP6622310B2 (enExample) |
| CN (1) | CN107072973A (enExample) |
| AU (3) | AU2015312430B2 (enExample) |
| CA (2) | CA3175785A1 (enExample) |
| DK (2) | DK3782617T3 (enExample) |
| ES (2) | ES2844500T3 (enExample) |
| FI (1) | FI3782617T3 (enExample) |
| HR (2) | HRP20210025T1 (enExample) |
| HU (2) | HUE066097T2 (enExample) |
| PL (2) | PL3188725T3 (enExample) |
| PT (2) | PT3188725T (enExample) |
| RS (1) | RS65337B1 (enExample) |
| SI (2) | SI3188725T1 (enExample) |
| WO (1) | WO2016036308A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016036308A1 (en) | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| KR20180004756A (ko) | 2015-05-06 | 2018-01-12 | 신애질 코포레이션 | 약물 입자를 함유하는 제약 현탁액, 그의 투여를 위한 장치, 및 그의 사용 방법 |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017177262A1 (en) | 2016-04-11 | 2017-10-19 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| WO2018017850A1 (en) * | 2016-07-20 | 2018-01-25 | Abbvie Inc. | Levodopa and carbidopa intestinal gel and methods of use |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| ES2886088T3 (es) | 2017-02-13 | 2021-12-16 | Bayer Animal Health Gmbh | Composición líquida que contiene pradofloxacina |
| WO2019129120A1 (en) * | 2017-12-28 | 2019-07-04 | Rpxds Co., Ltd | Tolcapone for prevention and/or treatment of obesity and related metabolic diseases |
| EP3768263B1 (en) * | 2018-03-23 | 2025-10-29 | LobSor Pharmaceuticals Aktiebolag | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders |
| EP3593819A1 (en) * | 2018-07-10 | 2020-01-15 | Medday Pharmaceuticals | Compositions for therapeutic uses containing 5-htp and carbidopa |
| MX368750B (es) * | 2018-08-31 | 2019-10-15 | Cell Therapy And Tech S A De C V | Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular. |
| JP2022514659A (ja) * | 2018-12-18 | 2022-02-14 | イーライ リリー アンド カンパニー | ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン |
| JP7506371B2 (ja) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | ドーパミン減少抑制剤 |
| CN115335036A (zh) * | 2020-03-13 | 2022-11-11 | 巴尔-波特拉及康邦亚股份有限公司 | 微粉化的奥匹卡朋 |
| CN111643493B (zh) * | 2020-05-26 | 2023-01-10 | 上海京新生物医药有限公司 | 一种高浓度左旋多巴制剂及其制备方法及其应用 |
| SI4200280T1 (sl) | 2020-10-07 | 2024-04-30 | Eli Lilly And Company | Derivati fenil-3,4-dihidroizokvinolin-2(1H)-il-etan-1-ona kot pozitivni alosterični modulatorji dopamin D1 receptorja |
| WO2022158991A1 (en) * | 2021-01-20 | 2022-07-28 | Bial-Portela & Ca., S.A. | Treatment of pain associated with parkinson's disease with opicapone in combination with levodopa |
| WO2025162373A1 (en) * | 2024-01-30 | 2025-08-07 | National Institute Of Biological Sciences, Beijing | Electrophile-containing catechol-o-methyltransferase (comt) inhibitors for targeting the keap1/nrf2 pathway |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9004348D0 (en) | 1990-02-27 | 1990-04-25 | Orion Yhtymae Oy | New use of catechol derivatives and their physiologically acceptable salts and esters |
| SE9203594D0 (sv) | 1992-11-30 | 1992-11-30 | Christer Nystroem | Laekemedel i dispersa system |
| HK1041441A1 (zh) * | 1998-11-10 | 2002-07-12 | Teva Pharmaceutical Industries, Ltd. | 包含l-多巴乙酯的可分散组合物 |
| FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| US20100221321A1 (en) | 2003-02-27 | 2010-09-02 | Innercap Technologies, Inc. | Apparatus And Methods For Delivering A Plurality Of Medicaments For Management Of Co-Morbid Diseases, Illnesses Or Conditions |
| ATE495739T1 (de) | 2003-08-29 | 2011-02-15 | Transform Pharmaceuticals Inc | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa |
| ES2360759T3 (es) * | 2003-08-29 | 2011-06-08 | Centocor Ortho Biotech Inc. | Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa. |
| WO2005099678A1 (en) | 2004-04-06 | 2005-10-27 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US20060222703A1 (en) | 2005-04-01 | 2006-10-05 | Iprbox Oy | Pharmaceutical composition and preparation method thereof |
| MX2008015339A (es) * | 2006-05-31 | 2008-12-16 | Solvay Pharm Gmbh | Administracion intestinal a largo plazo durante 24 horas de levodopa/carbidopa. |
| EP2104424A4 (en) | 2006-10-30 | 2011-06-15 | Wockhardt Research Center | PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA |
| ATE510537T1 (de) * | 2008-02-06 | 2011-06-15 | Wockhardt Research Center | Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit |
| RU2678839C2 (ru) * | 2009-05-19 | 2019-02-04 | Неуродерм Лтд | Композиции для непрерывного введения ингибиторов допа-декарбоксилазы |
| US20130253056A1 (en) | 2009-05-19 | 2013-09-26 | Neuroderm, Ltd. | Continuous Administration of Levodopa and/or Dopa Decarboxylase Inhibitors and Compositions for Same |
| PL2640358T3 (pl) | 2010-11-15 | 2018-06-29 | Neuroderm Ltd | Ciągłe podawanie l-dopy, inhibitorów dopa-dekarboksylazy, inhibitorów katecholo-o-metylotransferazy i ich kompozycji |
| WO2012147099A1 (en) | 2011-04-25 | 2012-11-01 | Suven Nishtaa Pharma Pvt. Ltd. | Pharmaceutical compositions of levodopa, carbidopa and entacapone |
| BR112015022390A8 (pt) | 2013-03-13 | 2019-11-26 | Neuroderm Ltd | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
| SE538425C2 (en) | 2014-09-04 | 2016-06-21 | Lobsor Pharmaceuticals Ab | Pharmaceutical compositions comprising levodopa, carbidopa and a comt inhibitor and method of administration thereof |
| WO2016036308A1 (en) | 2014-09-04 | 2016-03-10 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| WO2017039525A1 (en) | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
-
2015
- 2015-09-04 WO PCT/SE2015/050939 patent/WO2016036308A1/en not_active Ceased
- 2015-09-04 JP JP2017533154A patent/JP6622310B2/ja active Active
- 2015-09-04 ES ES15838800T patent/ES2844500T3/es active Active
- 2015-09-04 PT PT158388009T patent/PT3188725T/pt unknown
- 2015-09-04 SI SI201531474T patent/SI3188725T1/sl unknown
- 2015-09-04 SI SI201531992T patent/SI3782617T1/sl unknown
- 2015-09-04 HR HRP20210025TT patent/HRP20210025T1/hr unknown
- 2015-09-04 EP EP20200070.9A patent/EP3782617B1/en active Active
- 2015-09-04 AU AU2015312430A patent/AU2015312430B2/en active Active
- 2015-09-04 DK DK20200070.9T patent/DK3782617T3/da active
- 2015-09-04 HU HUE20200070A patent/HUE066097T2/hu unknown
- 2015-09-04 HU HUE15838800A patent/HUE052857T2/hu unknown
- 2015-09-04 FI FIEP20200070.9T patent/FI3782617T3/fi not_active Application Discontinuation
- 2015-09-04 HR HRP20240314TT patent/HRP20240314T1/hr unknown
- 2015-09-04 EP EP23219005.8A patent/EP4356907A1/en active Pending
- 2015-09-04 EP EP15838800.9A patent/EP3188725B1/en active Active
- 2015-09-04 ES ES20200070T patent/ES2973289T3/es active Active
- 2015-09-04 PL PL15838800T patent/PL3188725T3/pl unknown
- 2015-09-04 RS RS20240276A patent/RS65337B1/sr unknown
- 2015-09-04 DK DK15838800.9T patent/DK3188725T3/da active
- 2015-09-04 CA CA3175785A patent/CA3175785A1/en active Pending
- 2015-09-04 CA CA2959307A patent/CA2959307C/en active Active
- 2015-09-04 CN CN201580050984.7A patent/CN107072973A/zh active Pending
- 2015-09-04 US US15/507,959 patent/US10071069B2/en active Active
- 2015-09-04 PL PL20200070.9T patent/PL3782617T3/pl unknown
- 2015-09-04 PT PT202000709T patent/PT3782617T/pt unknown
-
2018
- 2018-08-03 US US16/054,392 patent/US10786472B2/en active Active
-
2019
- 2019-11-21 JP JP2019210309A patent/JP6889231B2/ja active Active
-
2020
- 2020-08-13 US US16/992,824 patent/US11413262B2/en active Active
- 2020-09-23 AU AU2020239682A patent/AU2020239682B2/en active Active
-
2022
- 2022-01-18 AU AU2022200291A patent/AU2022200291B2/en active Active
- 2022-06-07 US US17/834,839 patent/US12156858B2/en active Active
-
2024
- 2024-10-21 US US18/921,791 patent/US20250041257A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3188725T3 (pl) | Kompozycje farmaceutyczne zawierające lewodopę, inhibitor dekarboksylazy dopaminy i inhibitor comt oraz sposób ich podawania | |
| IL260025A (en) | A drug for the treatment of influenza characterized by the combination of a cap-dependent endonuclease inhibitor with an anti-influenza drug | |
| IL257521A (en) | Compositions comprising a pi3k inhibitor and an hdac inhibitor | |
| EP3344624B8 (en) | Tyk2 inhibitors and uses thereof | |
| EP3110820A4 (en) | Tyk2 inhibitors and uses thereof | |
| ZA201803485B (en) | Pharmaceutical compositions comprising levodopa amide and uses thereof | |
| EP3262049A4 (en) | Tyk2 inhibitors and uses thereof | |
| EP3331530A4 (en) | Mthfd2 inhibitors and uses thereof | |
| ZA202001074B (en) | Inhibitors of a-amino-b-carboxymuconic acid semialdehyde decarboxylase | |
| IL247668B (en) | Preparations that include dopa decarboxylase inhibitors | |
| SG11201708034SA (en) | Methods of administering glutaminase inhibitors | |
| PL3426243T3 (pl) | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania | |
| IL258513B (en) | History of quinoxaline and pyridopyrazine as pi3k inhibitors in the cell | |
| IL248785B (en) | Antecedents of ]-n5,1-dimethyl3--oxo-(3,2-dihydro-h1-pyrazol-4-yl)]-methyl-isoxazole-3-carboxamide and pharmaceutical preparations including these antecedents | |
| EP3272742A4 (en) | Histone deacetylase inhibitor, and preparation method and use thereof | |
| IL255530A (en) | Efflux-pump inhibitors and therapeutic uses thereof | |
| IL274701A (en) | Promote drugs, compositions and methods of their use | |
| IL247921A0 (en) | Glutaminase inhibitor compounds, preparations containing them and their uses | |
| EP3237391A4 (en) | Creatine prodrugs, compositions and methods of use thereof | |
| IL252752A0 (en) | Pharmaceutical preparations containing a combination of pyridazine and egfr inhibitor | |
| IL251162A0 (en) | Monoamine oxidase-B inhibitors and rehabilitation |